A5056529778- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Tryptophan and brain disorders
- Research in Social Sciences
- RNA Interference and Gene Delivery
- Cancer Research and Treatments
- Hernia repair and management
- Employment and Welfare Studies
- Appendicitis Diagnosis and Management
- Pregnancy-related medical research
- Cancer, Stress, Anesthesia, and Immune Response
- vaccines and immunoinformatics approaches
- Immune cells in cancer
- Education, Healthcare and Sociology Research
- Balkans: History, Politics, Society
- SARS-CoV-2 and COVID-19 Research
- Virus-based gene therapy research
Copenhagen University Hospital
2015-2025
Herlev Hospital
2014-2024
Gentofte Hospital
2018-2021
University of Copenhagen
2015-2019
Abstract Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells tumor expressing IDO and/or PD-L1 (IDO/PD-L1), combined with nivolumab. Thirty aPD1 therapy-naive MM were treated in phase 1/2 study (...
Arginase-1-producing cells inhibit T cell-mediated anti-tumor responses by reducing L-arginine levels in the tumor microenvironment. cell-facilitated elimination of arginase-1-expressing could potentially restore and improve responses. The activation arginase-1-specific may convert immunosuppressive microenvironment induce or strengthen local Th1 inflammation. In current clinical study, we examined safety immunogenicity arginase-1-based peptide vaccination.In this phase I trial, ten patients...
We have previously published initial efficacy of the indoleamine 2,3-dioxygenase (IDO)/anti-programmed death ligand 1 (PD-L1) vaccine in combination with nivolumab 30 anti-PD-1 therapy naïve patients metastatic melanoma (cohort A). now report long-term follow-up cohort A. Further, we results from B, where peptide was added to for progressive disease during treatment.
Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has shown remarkable results in malignant melanoma (MM), while studies on the potential other cancer diagnoses are sparse. Further, prospect of using checkpoint inhibitors (CPIs) to support TIL production and remains be explored. Study design TIL-based ACT CPIs was evaluated a clinical phase I/II trial. Ipilimumab (3 mg/kg) administered prior tumor resection nivolumab mg/kg, every 2 weeks ×4) relation infusion....
Background The B-cell lymphoma-extra-large (Bcl-XL) protein plays an important role in cancer cells’ resistance to apoptosis. Pre-clinical studies have shown that vaccination with Bcl-XL-derived peptides can induce tumor-specific T cell responses may lead the elimination of cells. Furthermore, pre-clinical novel adjuvant CAF ® 09b intraperitoneal (IP) injections this improve activation immune system. In study, patients hormone-sensitive prostate (PC) received a vaccine consisting...
<h3>Background</h3> Immunotherapy has transformed the field of cancer treatment over last decade. However, despite success immune checkpoint inhibitors (ICIs), many patients do not benefit from treatment. The immunological determinants whether a patient responds can be studied by examining characteristics responders and non-responders. Several immunologic factors may affect outcome, such as peripheral cell populations, polarization state these cells, expression checkpoints. This investigated...
Abstract Background: Immunotherapy is an effective treatment for patients with metastatic melanoma. However, immune checkpoint inhibitors (ICI) often induce immune-related adverse events and despite high response rates many still progress. Nivolumab combined a peptide vaccine designed to engage activate IDO- PD-L1 specific T cells promising approach treating advanced melanoma without inducing the amount of toxicity observed in combination ICI treatment. Methods: In investigator-initiated...
Abstract Anti-PD-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, >50% of the patients progress due to resistance. Improved combination therapies enhancing aPD1 efficacy without leading increased toxicity are needed. In this non-randomized phase I/II study (ClinicalTrials.gov: NCT03047928), we treated 30 naive MM with a novel immune-modulatory vaccine (IO102/IO103) activating indoleamine 2,3-dioxygenase (IDO) and programmed death ligand-1 (PD-L1) specific...
Ectopic decidual reaction has been described in various intraperitoneal locations. We present a case of unusual ectopic the groin mimicking inguinal lymphoma on ultrasound pregnant woman. This contributes evidence illustrating variability clinical presentation reaction.